Semin Liver Dis 2010; 30: 035-051DOI: 10.1055/s-0030-1247131ABSTRACTHepatocellular carcinoma (HCC) is one of most lethal cancers worldwide. Strategic decisions for the advancement of molecular therapies in this neoplasm require a clear understanding of its molecular classification. Studies indicate aberrant activation of signaling pathways involved in cellular proliferation (e.g., epidermal growth factor and RAS/mitogen-activated protein kinase pathways), survival (e.g., Akt/mechanistic target of rapamycin pathway), differentiation (e.g., Wnt and Hedgehog pathways), and angiogenesis (e.g., vascular endothelial growth factor and platelet-derived growth factor), which is heterogeneously presented in each tumor. Integrative analysis of accumulated genomic datasets has revealed a global scheme…

Further information:

Article source

Related posts:

1. Molecular expression profiling with respect to KEGG hsa05219 pathway
2. Pathology of Early Hepatocellular Carcinoma: Conventional and Molecular Diagnosis
3. Identification of Novel Oncogenes and Tumor Suppressors in Hepatocellular Carcinoma
4. Mouse Models of Hepatocellular Carcinoma
5. Upstream molecular signaling pathways of p27(Kip1) expression: effects of 4-hydroxytamoxifen, dexamethasone, and retinoic acids